Location: Home
  • search
  • go
  • Relate News
  • 8/2/2021Review of China Healthcare Financing 2014-2021
  • 8/2/2021SMEI: Chinese Retail Pharmacy Market (Offline and Online) Rose 12.5% i...
  • 8/2/2021SMEI Predicts Restructure of Chinese Drug Retail Market and Further Bo...
  • 8/2/2021Eisai's Anti-Epileptic Fycompa Approved in China as Monotherapy for Pa...
  • 8/2/2021WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Cert...
  • 8/2/2021CANbridge CAN103 Investigational NDA Accepted by NMPA
  • 8/2/2021Zentera Secures $75M Series B Financing as It Eyes HK IPO
  • 8/1/2021NHSA Publicizes the List of Drugs Passing Form Evaluation for Inclusio...
  • 8/1/2021Can AstraZeneca Sustain Rapid Growth in China amid Price-Cutting Schem...
  • 7/30/2021China Begins to Deploy Patent Linkage as NMPA Tempted to Set Higher Ba...
  • 7/30/2021Financial-related Company News in Brief (July 2021)
  • 7/30/2021Review of Chinese Drug Registration Application and Evaluation in H1/2...
  • 7/30/2021Recent Executive Moves
  • 7/29/2021SMEI: Chinese Drug Market under Transformation with Growing ex-Hospita...
  • 7/29/2021Junshi's Chinese sNDA for Toripalimab Plus Chemotherapy as First-Lin...
  • 7/29/2021Guobang Pharma's IPO to Debut on Shanghai Stock Exchange
  • 7/29/2021AstraZeneca's China Business Growth Slows in Q2/2021 amid VBP Uncertai...
  • 7/29/2021Ping An-Shionogi Joint Venture Launched in Shanghai
  • 7/29/2021Eli Lilly hands Kumquat Biosciences $70M to kick off cancer drug R&D a...
  • 7/29/2021Complix Signs Global Drug R&D Pact with Nhwa Pharma to Develop Novel A...
  • 7/29/2021Parexel Enters Patient Centric Partnership with CAMS Cancer Hospital
  • 7/29/2021Novita and CR Double Crane in License Deal for Fascin Inhibitor in C...
  • 7/29/2021I-Mab's Chinese IND for P2 Trial of Efineptakin Alfa in Combo with PD-...
  • 7/29/2021Health Care in the Year of the Ox: Navigating China's Dynamic M&A Mark...
  • 7/29/2021China's New Grounds for Defence and Damages Indicates Tougher Rules on...
  • 7/29/2021Antibody Licensing Deals in China: H1 2021 Summary by PharmaDJ/CAS
  • 7/29/2021China's 2021-2025 Five-Year Plan - An Outlook to China's Planned Futur...
  • 7/28/2021NHC Issues the Guidelines for Comprehensive Clinical Appraisal of Drug...
  • 7/28/2021Daewoong Reports Positive Chinese Ph3 Trial Outcome of Its Botulinum...
  • 7/27/2021NMPA Revises Packages Insert of Vitamin B6 Injection
  • Page:176/774 Total number of articles:23207: [First][<<] [174] [175] [176] [177] [178] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group